Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures

 
• By Mandy Jackson

The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working in this area with almost no success for decades, yet still feels a commitment to keep trying, Lilly Research Labs President Daniel Skovronsky tells Scrip.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.

More from Neurological

More from Therapy Areas